LT2772535T - Abc5 atžvilgiu teigiamos mezenchiminės kamieninės ląstelės kaip imunomoduliatoriai - Google Patents

Abc5 atžvilgiu teigiamos mezenchiminės kamieninės ląstelės kaip imunomoduliatoriai

Info

Publication number
LT2772535T
LT2772535T LTEP14168199.9T LT14168199T LT2772535T LT 2772535 T LT2772535 T LT 2772535T LT 14168199 T LT14168199 T LT 14168199T LT 2772535 T LT2772535 T LT 2772535T
Authority
LT
Lithuania
Prior art keywords
abc5
immunomodulators
stem cells
mesenchymal stem
positive mesenchymal
Prior art date
Application number
LTEP14168199.9T
Other languages
English (en)
Inventor
Markus Frank
Original Assignee
Children's Medical Center Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Children's Medical Center Corporation filed Critical Children's Medical Center Corporation
Publication of LT2772535T publication Critical patent/LT2772535T/lt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0668—Mesenchymal stem cells from other natural sources
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0625—Epidermal cells, skin cells; Cells of the oral mucosa
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/36—Skin; Hair; Nails; Sebaceous glands; Cerumen; Epidermis; Epithelial cells; Keratinocytes; Langerhans cells; Ectodermal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Vascular Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
LTEP14168199.9T 2006-05-31 2007-05-31 Abc5 atžvilgiu teigiamos mezenchiminės kamieninės ląstelės kaip imunomoduliatoriai LT2772535T (lt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US80940706P 2006-05-31 2006-05-31

Publications (1)

Publication Number Publication Date
LT2772535T true LT2772535T (lt) 2022-08-25

Family

ID=38594403

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEP14168199.9T LT2772535T (lt) 2006-05-31 2007-05-31 Abc5 atžvilgiu teigiamos mezenchiminės kamieninės ląstelės kaip imunomoduliatoriai

Country Status (12)

Country Link
US (4) US8455245B2 (lt)
EP (2) EP2035549B1 (lt)
AU (1) AU2007254894B9 (lt)
CA (1) CA2685492C (lt)
DK (2) DK2772535T3 (lt)
ES (2) ES2918323T3 (lt)
HU (1) HUE059011T2 (lt)
LT (1) LT2772535T (lt)
PL (2) PL2035549T3 (lt)
PT (2) PT2772535T (lt)
SI (2) SI2772535T1 (lt)
WO (1) WO2007143139A1 (lt)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2411101C (en) 2000-06-05 2018-01-16 Brigham And Women's Hospital, Inc. A gene encoding a multidrug resistance human p-glycoprotein homologue on chromosome 7p15-21 and uses thereof
SI2772535T1 (sl) * 2006-05-31 2022-08-31 Children's Medical Center Corporation ABC5 pozitivne mezenhimske matične celice kot imunomodulatorji
EP2155248B1 (en) 2007-04-12 2015-06-10 The Brigham and Women's Hospital, Inc. Targeting abcb5 for cancer therapy
EP3978928A1 (en) 2008-11-14 2022-04-06 The Brigham and Women's Hospital, Inc. Therapeutic and diagnostic methods relating to cancer stem cells
US11542328B2 (en) 2008-11-14 2023-01-03 The Brigham And Women's Hospital, Inc. Therapeutic and diagnostic methods relating to cancer stem cells
WO2014130518A1 (en) * 2013-02-19 2014-08-28 Children's Medical Center Corporation Abcb5(+) stem cells for treating ocular disease
AU2014262590B2 (en) * 2013-05-10 2018-05-10 Children's Medical Center Corporation Wound healing and tissue engineering
US20150310380A1 (en) * 2014-04-28 2015-10-29 Patent Investment & Licensing Company Dispatch system having control shared with dispatched service providers
KR101723265B1 (ko) * 2013-08-16 2017-04-04 가톨릭대학교 산학협력단 mTOR/STAT3 신호억제제 처리된 면역조절능을 갖는 간엽줄기세포 및 이를 포함하는 면역질환의 예방 또는 치료용 세포치료제 조성물
WO2015088414A1 (en) * 2013-12-13 2015-06-18 Isletone Ab Immunomodulatory compositions
WO2015148512A1 (en) 2014-03-24 2015-10-01 Qt Holdings Corp Shaped articles including hydrogels and methods of manufacture and use thereof
US9790467B2 (en) 2015-09-22 2017-10-17 Qt Holdings Corp Methods and compositions for activation or expansion of T lymphocytes
MX2020011297A (es) 2018-04-25 2020-11-18 Childrens Medical Center Ligandos y substratos de abcb5.
US12486519B2 (en) * 2018-08-18 2025-12-02 President And Fellows Of Harvard College In situ gene editing
US20200061365A1 (en) * 2018-08-24 2020-02-27 Instant Systems, Inc. Cell storage container for use with sterile docking systems
US20220184136A1 (en) * 2019-03-28 2022-06-16 Children's Medical Center Corporation Highly functional manufactured abcb5+ mesenchymal stem cells
EP3958881A4 (en) * 2019-04-24 2023-01-18 Children's Medical Center Corporation ABCB5+ STEM CELL THERAPIES FOR LIVER DISEASE
EP4125960A4 (en) * 2020-03-30 2024-04-03 Children's Medical Center Corporation USING STEM CELLS TO TREAT EXCESSIVE INFLAMMATION
JP2024517954A (ja) * 2021-05-13 2024-04-23 プライムジェン ユーエス インコーポレイテッド 肝疾患を治療するための方法および組成物
US20230256065A1 (en) * 2022-02-16 2023-08-17 Elena RUSYN Autologous stem cell vaccine and methods
CN115260098B (zh) * 2022-06-09 2024-06-04 澳门科技大学 Abcb5抑制剂在制备多耐药性类风湿性关节炎治疗药物中的应用

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4352883A (en) 1979-03-28 1982-10-05 Damon Corporation Encapsulation of biological material
DE3587465T2 (de) 1984-09-10 1994-01-20 Hsc Res Dev Corp Vielfache Drogen-Resistenz in Säugetierzellinien und Isolierung der determinanten Glykoprotein-DNS.
US4837306A (en) 1985-02-25 1989-06-06 The Ontario Cancer Institute Method for selecting hybridomas producing antibodies specific to the P-glycoprotein cell suface antigen and a cDNA clone encoding the C-terminal portion of the antigen
US5837258A (en) 1991-08-30 1998-11-17 University Of South Florida Induction of tissue, bone or cartilage formation using connective tissue growth factor
IT1257893B (it) 1992-06-17 1996-02-16 Ist Superiore Sanita Anticorpi monoclonali che riconoscono un epitopo della p-glicoproteina umana.
WO1994009363A1 (en) 1992-10-14 1994-04-28 Board Of Regents, The University Of Texas System Cancer diagnosis and therapy
US5906934A (en) 1995-03-14 1999-05-25 Morphogen Pharmaceuticals, Inc. Mesenchymal stem cells for cartilage repair
ES2329953T3 (es) 1996-04-19 2009-12-02 Osiris Therapeutics, Inc. Regeneracion e incremento de hueso utilizando celulas madre mesenquimales.
US6152142A (en) 1997-02-28 2000-11-28 Tseng; Scheffer C. G. Grafts made from amniotic membrane; methods of separating, preserving, and using such grafts in surgeries
AU749675B2 (en) 1998-03-13 2002-07-04 Mesoblast International Sarl Uses for human non-autologous mesenchymal stem cells
US6368636B1 (en) 1998-03-18 2002-04-09 Osiris Therapeutics, Inc. Mesenchymal stem cells for prevention and treatment of immune responses in transplantation
AU2999199A (en) 1998-04-03 1999-10-25 Osiris Therapeutics, Inc. Mesenchymal stem cells as immunosuppressants
GB9808836D0 (en) 1998-04-27 1998-06-24 Amersham Pharm Biotech Uk Ltd Microfabricated apparatus for cell based assays
PT1082410E (pt) 1998-05-29 2007-11-09 Osiris Therapeutics Inc Células estaminais mesenquimatosas humanas cd45+ e/ou fibroblastos+
CA2411101C (en) 2000-06-05 2018-01-16 Brigham And Women's Hospital, Inc. A gene encoding a multidrug resistance human p-glycoprotein homologue on chromosome 7p15-21 and uses thereof
ATE446366T1 (de) 2000-06-22 2009-11-15 Genentech Inc Agonistische monoklonale antikörper gegen trkc
SE517275C2 (sv) * 2000-09-20 2002-05-21 Obducat Ab Sätt vid våtetsning av ett substrat
JP2004531213A (ja) 2000-10-27 2004-10-14 インサイト・ゲノミックス・インコーポレイテッド 輸送体及びイオンチャネル
US6905678B2 (en) 2001-07-07 2005-06-14 Crucell Holland B.V. Gene delivery vectors with cell type specificity for mesenchymal stem cells
US7592174B2 (en) * 2002-05-31 2009-09-22 The Board Of Trustees Of The Leland Stanford Junior University Isolation of mesenchymal stem cells
ES2350687T3 (es) 2002-07-03 2011-01-26 Ono Pharmaceutical Co., Ltd. Composiciones de inmunopotenciación.
CN1753912B (zh) 2002-12-23 2011-11-02 惠氏公司 抗pd-1抗体及其用途
GB0325130D0 (en) 2003-10-28 2003-12-03 Smith & Nephew Apparatus with scaffold
EP1702061A4 (en) 2003-11-24 2007-05-02 Univ Rockefeller METHOD OF INSULATING A SELF-RENEWING, MULTIPOTENTIAL, SLOWLY CIRCULATING CELL
DK2311873T3 (en) 2004-01-07 2018-11-26 Novartis Vaccines & Diagnostics Inc M-CSF-SPECIFIC MONOCLONAL ANTIBODY AND APPLICATIONS THEREOF
US20050186672A1 (en) 2004-01-27 2005-08-25 Reliance Life Sciences Pvt. Ltd. Tissue system with undifferentiated stem cells derived from corneal limbus
CA3218940A1 (en) 2004-11-12 2006-05-18 Cambridge University Technical Services Ltd. Methods and means related to cancer stem cells
WO2006103685A2 (en) 2005-03-28 2006-10-05 Vision Research Foundation A method for cultivating cells derived from corneal limbal tissue and cells deived from corneal limbal tissue
KR101441843B1 (ko) * 2005-10-18 2014-09-17 내셔날 쥬이쉬 헬스 조건부 불멸화 장기 줄기 세포 및 상기 세포의 제조 및 사용 방법
SI2772535T1 (sl) 2006-05-31 2022-08-31 Children's Medical Center Corporation ABC5 pozitivne mezenhimske matične celice kot imunomodulatorji
WO2008030616A2 (en) 2006-09-07 2008-03-13 Stemline Therapeutics, Inc. Monitoring cancer stem cells
EP2155248B1 (en) 2007-04-12 2015-06-10 The Brigham and Women's Hospital, Inc. Targeting abcb5 for cancer therapy
US9011840B2 (en) 2008-03-14 2015-04-21 The Board Of Trustees Of The University Of Illinois Activated mesenchymal stem cells for wound healing and impaired tissue regeneration
EP3978928A1 (en) 2008-11-14 2022-04-06 The Brigham and Women's Hospital, Inc. Therapeutic and diagnostic methods relating to cancer stem cells
US11542328B2 (en) 2008-11-14 2023-01-03 The Brigham And Women's Hospital, Inc. Therapeutic and diagnostic methods relating to cancer stem cells
WO2014130518A1 (en) 2013-02-19 2014-08-28 Children's Medical Center Corporation Abcb5(+) stem cells for treating ocular disease
AU2014262590B2 (en) 2013-05-10 2018-05-10 Children's Medical Center Corporation Wound healing and tissue engineering
MX2020011297A (es) 2018-04-25 2020-11-18 Childrens Medical Center Ligandos y substratos de abcb5.
US20220184136A1 (en) 2019-03-28 2022-06-16 Children's Medical Center Corporation Highly functional manufactured abcb5+ mesenchymal stem cells

Also Published As

Publication number Publication date
EP2035549A1 (en) 2009-03-18
HK1129703A1 (en) 2009-12-04
AU2007254894B2 (en) 2014-10-23
PL2772535T3 (pl) 2022-09-05
EP2772535B1 (en) 2022-04-06
US11624054B2 (en) 2023-04-11
PT2772535T (pt) 2022-07-04
HUE059011T2 (hu) 2022-09-28
SI2035549T1 (sl) 2015-03-31
US8455245B2 (en) 2013-06-04
PL2035549T3 (pl) 2014-12-31
SI2772535T1 (sl) 2022-08-31
CA2685492C (en) 2018-01-16
US20180320131A1 (en) 2018-11-08
US20080003206A1 (en) 2008-01-03
DK2772535T3 (da) 2022-07-04
AU2007254894B9 (en) 2014-11-13
WO2007143139A1 (en) 2007-12-13
US20230313136A1 (en) 2023-10-05
PT2035549E (pt) 2014-10-06
ES2511791T3 (es) 2014-10-23
EP2035549B1 (en) 2014-07-09
DK2035549T3 (da) 2014-10-13
US20130315880A1 (en) 2013-11-28
HK1201295A1 (en) 2015-08-28
AU2007254894A1 (en) 2007-12-13
CA2685492A1 (en) 2007-12-13
ES2918323T3 (es) 2022-07-15
US10017738B2 (en) 2018-07-10
EP2772535A1 (en) 2014-09-03

Similar Documents

Publication Publication Date Title
HUE059011T2 (hu) Immunmodulátorként szolgáló ABC5-pozitív mezenchimális õssejtek
PL2254586T3 (pl) Cząstki mezenchymalnych komórek macierzystych
PL2046946T3 (pl) Hodowla pluripotencjalnych komórek macierzystych
GB0814249D0 (en) Uses of mesenchymal stem cells
GB2458863B (en) Improved culture of stem cells
IL228818A0 (en) Stem cell cultures
SG10201500674YA (en) Pluripotent stem cells
IL212368A0 (en) Compounds that expand hematopoietic stem cells
ZA201000715B (en) Single pluripotent stem cell culture
ZA201008391B (en) Pluripotent cells
SG10201403202XA (en) Pre-natal mesenchymal stem cells
IL247310B (en) Mesenchymal stem cell differentiation
EP2007411A4 (en) REGULATORY STEM CELLS
EP2294182A4 (en) CULTS OF MULTIPOTENT STEM CELLS
GB0602208D0 (en) Embryonic stem cells
GB0724994D0 (en) Mesenchymal stem cell markers
GB0818256D0 (en) stem cells
GB2467284B (en) Sulfatase enzymes
HK1154890A (en) Multipotent stem cell cultures
GB0918471D0 (en) Stem cells
IL193947A0 (en) Regulating stem cells
AU2006902280A0 (en) Stem cells